Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	88.21	139.26	203.13	127.44	80.93
Short-Term Investments	688.72	643.86	816.89	445.49	483.95
Cash & Cash Equivalents	776.93	783.12	1,020	572.93	564.88
Cash Growth	-0.79%	-23.22%	78.04%	1.43%	-3.49%
Receivables	2.81	2.21	4.38	0	15.32
Inventory	19.08	8.49	0	0	7.33
Other Current Assets	35.02	38.96	39.84	63.75	24.18
Total Current Assets	833.84	832.77	1,064	636.68	611.7
Property, Plant & Equipment	69.79	88.12	104.23	116.07	126.11
Long-Term Investments	29.44	313.87	266.38	97.61	152.93
Other Long-Term Assets	4.06	3.96	2.9	2.6	0
Total Long-Term Assets	103.28	405.95	373.51	216.28	279.04
Total Assets	937.12	1,239	1,438	852.95	890.74
Accounts Payable	9.78	18.62	16.7	17.72	21.9
Deferred Revenue	0	0	0	0	61.51
Current Debt	15.01	13.66	11.16	7.41	6.92
Other Current Liabilities	43.17	30.35	31.97	69.26	2.56
Total Current Liabilities	67.96	62.63	59.83	94.39	92.89
Long-Term Debt	56.99	72	85.94	97.79	106.75
Other Long-Term Liabilities	1.16	3.28	0	261.27	50.58
Total Long-Term Liabilities	58.14	75.28	85.94	359.06	157.33
Total Liabilities	126.1	137.9	145.76	453.45	250.21
Total Debt	72	85.66	97.09	105.2	113.66
Debt Growth	-15.95%	-11.78%	-7.70%	-7.45%	-
Retained Earnings	-822.65	-470.56	-238.76	-1,843.48	-1,516.11
Comprehensive Income	-0.44	-12.54	-1.2	0.11	0.2
Shareholders' Equity	811.02	1,101	1,292	399.5	640.53
Net Cash / Debt	704.93	697.46	922.92	467.73	451.22
Net Cash / Debt Growth	1.07%	-24.43%	97.32%	3.66%	-22.91%
Net Cash Per Share	12.67	12.73	15.27	6.78	7.52
Working Capital	765.88	770.14	1,004	542.28	518.82
Book Value Per Share	14.57	20.09	21.37	5.79	10.68

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).